Information  X 
Enter a valid email address

Company Name matching 'Saniona AB'

Date
Time Source
Company
Announcement
20 May 2022 8:45 am GNW   Saniona AB Saniona provides update on ongoing review of tesofensine in Mexico
30 Apr 2022 7:00 am GNW   Saniona AB Saniona publishes its Annual Report for 2021
27 Apr 2022 7:00 am GNW   Saniona AB Saniona Changes Date of Annual Report for 2021
25 Apr 2022 5:15 pm GNW   Saniona AB Notice of Saniona AB annual shareholders’ meeting
  3:25 pm GNW   Saniona AB Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team
29 Mar 2022 3:00 pm GNW   Saniona AB Saniona Announces Strategic Program Prioritization and Restructuring to Streamline Operational Costs
24 Mar 2022 7:00 am GNW   Saniona AB Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial
21 Mar 2022 7:00 am GNW   Saniona AB Saniona ion channel research collaboration with Boehringer Ingelheim advances to next stage
01 Mar 2022 7:00 am GNW   Saniona AB Saniona to participate in multiple upcoming investor conferences
24 Feb 2022 7:00 am GNW   Saniona AB Saniona publishes its year-end report for 2021
10 Feb 2022 7:00 am GNW   Saniona AB Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial
05 Jan 2022 3:45 pm GNW   Saniona AB Saniona to participate in multiple upcoming virtual investor conferences
28 Dec 2021 4:00 pm GNW   Saniona AB Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome
02 Dec 2021 9:45 pm GNW   Saniona AB Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
25 Nov 2021 7:00 am GNW   Saniona AB Saniona AB’s Nomination Committee for the Annual General Meeting 2022
18 Nov 2021 7:00 am GNW   Saniona AB Saniona publishes its interim report for the third quarter of 2021
17 Nov 2021 7:00 am GNW   Saniona AB Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity
18 Oct 2021 1:00 pm GNW   Saniona AB Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA
06 Oct 2021 1:00 pm GNW   Saniona AB Saniona to participate in multiple upcoming virtual investor conferences
16 Sep 2021 4:50 pm GNW   Saniona AB Saniona appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee
  4:45 pm GNW   Saniona AB Bulletin from the Saniona AB extraordinary shareholders’ meeting on September 16, 2021
15 Sep 2021 1:00 pm GNW   Saniona AB Saniona appoints Wendy Dwyer as Chief Business Officer
26 Aug 2021 7:00 am GNW   Saniona AB Saniona publishes its interim report for the second quarter of 2021
20 Aug 2021 1:00 pm GNW   Saniona AB Notice of Saniona AB extraordinary shareholders’ meeting to elect new member of the board of directors
26 Jul 2021 7:00 am GNW   Saniona AB Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity
14 Jul 2021 1:00 pm GNW   Saniona AB Saniona secures SEK 87 million ($10 million) non-dilutive term loan
30 Jun 2021 11:45 am GNW   Saniona AB Saniona Initiates Phase 1 Clinical Trial of SAN711
29 Jun 2021 3:15 pm GNW   Saniona AB Bulletin from the Saniona AB extraordinary shareholders’ meeting on June 29, 2021
25 Jun 2021 6:45 pm GNW   Saniona AB Saniona provides update on ongoing review of tesofensine in Mexico
08 Jun 2021 1:00 pm GNW   Saniona AB Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology
26 May 2021 6:30 pm GNW   Saniona AB Notice of Saniona AB extraordinary shareholders’ meeting
  5:30 pm GNW   Saniona AB Bulletin from the Saniona AB annual shareholders’ meeting on May 26, 2021, and information regarding planned extraordinary shareholders’ meeting
  7:00 am GNW   Saniona AB Saniona publishes its interim report for the first quarter of 2021
20 May 2021 7:30 pm GNW   Saniona AB Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs
12 May 2021 1:00 pm GNW   Saniona AB Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases
10 May 2021 1:00 pm GNW   Saniona AB Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and Hypothalamic Obesity on Patients and Caregivers
30 Apr 2021 7:00 am GNW   Saniona AB Change in numbers of shares and votes in Saniona AB (publ)
29 Apr 2021 4:55 pm GNW   Saniona AB Saniona publishes its Annual Report for 2020
26 Apr 2021 1:00 pm GNW   Saniona AB Saniona to Present at Multiple Upcoming Investor Conferences
23 Apr 2021 7:00 am GNW   Saniona AB Notice of Saniona AB annual shareholders’ meeting
22 Apr 2021 7:00 am GNW   Saniona AB Saniona announces outcome of TO3 warrant exercise
  12:00 am GNW   Saniona AB Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA
19 Apr 2021 1:00 pm GNW   Saniona AB Saniona Announces Partnership with the Foundation for Prader-Willi Research (FPWR) to Support its Prader-Willi Syndrome (PWS) Clinical Trial with Tesomet
14 Apr 2021 1:00 pm GNW   Saniona AB Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
12 Apr 2021 7:00 am GNW   Saniona AB Saniona Completes Sale of Remaining Shares in Scandion Oncology
31 Mar 2021 7:00 am GNW   Saniona AB Saniona announces that the exercise period of warrants of series TO3 begins on April 6, 2021
19 Mar 2021 4:30 pm GNW   Saniona AB Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
17 Mar 2021 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its year-end report for 2020
15 Mar 2021 12:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona Announces Oral Presentation of Tesomet Data in Hypothalamic Obesity at ENDO 2021
10 Mar 2021 1:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona to Present at the Oppenheimer 31st Annual Healthcare Conference
08 Mar 2021 1:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity
03 Mar 2021 12:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome
22 Feb 2021 10:59 pm GNW Factsheet Saniona AB (0RQJ) Saniona postpones 2020 year-end financial report due to restatement and re-audit of prior period financial statements in line with U.S. PCAOB audit standards
25 Jan 2021 1:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction
07 Jan 2021 1:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona to present at three upcoming investor conferences
21 Dec 2020 1:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Executive Team
17 Dec 2020 9:15 pm GNW Factsheet Saniona AB (0RQJ) Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%
16 Dec 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5% Following Scandion’s Successful Rights Issue
30 Nov 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its interim report for the third quarter 2020
26 Nov 2020 3:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona AB’s Nomination Committee for the Annual General Meeting 2021


Company Announcements Archive »


a d v e r t i s e m e n t